Key result
Post-treatment aspirin use was associated with a reduced risk of delayed cerebral ischemia and improved 6-month outcomes in patients with subarachnoid hemorrhage.
Why the study?
Does post-treatment antiplatelet therapy reduce delayed cerebral ischemia and improve outcomes in patients with aneurysmal subarachnoid hemorrhage?
Case-Control (n=580)
Does post-treatment antiplatelet therapy reduce delayed cerebral ischemia and improve outcomes in patients with aneurysmal subarachnoid hemorrhage?
Post-treatment aspirin administration in patients with aneurysmal subarachnoid hemorrhage may reduce the risk of delayed cerebral ischemia and improve 6-month outcomes without increasing major bleeding, whereas dual antiplatelet therapy increases major bleeding risk.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for aspirin after subarachnoid hemorrhage; randomized trials needed before any practice change.
BACKGROUND: Delayed cerebral ischemia (DCI) has a strong impact on outcome of patients with aneurysmal subarachnoid hemorrhage (SAH). Positive effect of antiplatelet therapy on DCI rates has been supposed upon smaller SAH series. OBJECTIVE: To analyze the benefit/risk profile of antiplatelet use in SAH patients. METHODS: This retrospective case-control study was based on institutional observational cohort with 994 SAH patients treated between January 2003 and June 2016. The individuals with postcoiling antiplatelet therapy (aspirin with/without clopidogrel) were compared to a control group without antiplatelet therapy. Occurrence of DCI, major/minor bleeding events in the follow-up computed tomography scans, and favorable outcome at 6 mo after SAH (modified Rankin scale < 3) were compared in both groups. RESULTS: Of 580 patients in the final analysis, 329 patients received post-treatment antiplatelet medication. There were no significant differences between the compared groups with regard to basic outcome confounders. Aspirin use was independently associated with reduced DCI risk (P < .001, adjusted odds ratio = 0.41, 95% confidence interval 0.24-0.65) and favorable outcome (P = .02, adjusted odds ratio = 1.78, 95% confidence interval 1.06-2.98). Regarding bleeding complications, aspirin was associated only with minor bleeding events (P = .02 vs P = .51 for major bleeding events). CONCLUSION: Regular administration of aspirin might have a positive impact on DCI risk and outcome of SAH patients, without increasing the risk for clinically relevant bleeding events. In our SAH cohort, dual antiplatelet therapy showed no additional benefit on DCI risk, but increased the likelihood of major bleeding events.
No takes yet. Share an insight, caveat, or question.
Oppong et al. (2018) conducted a case-control in Aneurysmal subarachnoid hemorrhage (SAH) (n=580). Post-treatment antiplatelet therapy (aspirin with/without clopidogrel) vs. Control group without antiplatelet therapy was evaluated on Delayed cerebral ischemia (DCI) (OR 0.41, 95% CI 0.24-0.65, p=<.001). Post-treatment aspirin use was associated with a reduced risk of delayed cerebral ischemia and improved 6-month outcomes in patients with subarachnoid hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: